Biochemistry, Peptide, Vasoactive intestinal peptide, Internal medicine and Endocrinology are his primary areas of study. His Biochemistry research includes themes of Stereochemistry and Neuroprotection. His Neuroprotection research is multidisciplinary, relying on both Oxidative stress, Dopamine, Antioxidant and Monoamine oxidase.
His Peptide study combines topics from a wide range of disciplines, such as Antibacterial agent, Sequence, Peptide sequence, PEGylation and Immunotherapy. His study in Vasoactive intestinal peptide is interdisciplinary in nature, drawing from both Antagonist, Receptor antagonist, Moiety and Neurotransmission. His Receptor study integrates concerns from other disciplines, such as Central nervous system and Binding site.
Mati Fridkin mainly investigates Biochemistry, Peptide, Internal medicine, Endocrinology and Receptor. He interconnects Acetylcholine receptor, Molecular biology, Stereochemistry and Binding site in the investigation of issues within Peptide. The Molecular biology study combines topics in areas such as Epitope and In vitro.
His Endocrinology study frequently involves adjacent topics like Vasoactive intestinal peptide. His work deals with themes such as Antagonist and Neuroprotection, which intersect with Vasoactive intestinal peptide. As part of the same scientific family, Mati Fridkin usually focuses on Tuftsin, concentrating on Immunology and intersecting with Phosphorylcholine.
His primary scientific interests are in Biochemistry, Pharmacology, Peptide, Tuftsin and Stereochemistry. His research on Biochemistry frequently connects to adjacent areas such as Acute-phase protein. His Pharmacology research is multidisciplinary, incorporating perspectives in PEGylation, Acetylcholinesterase and Monoamine oxidase.
His studies deal with areas such as Receptor, Internal medicine, Biophysics and Endocrinology as well as Peptide. Specifically, his work in Receptor is concerned with the study of Vasoactive intestinal peptide. His studies in Tuftsin integrate themes in fields like Tumor necrosis factor alpha, Phagocytosis, Immunology, Phosphorylcholine and Biological activity.
Mati Fridkin spends much of his time researching Pharmacology, Biochemistry, Neuroprotection, Peptide and Oxidative stress. His biological study deals with issues like Monoamine oxidase, which deal with fields such as In vitro. Mati Fridkin studies Biochemistry, namely Lipid peroxidation.
His Neuroprotection research includes elements of Dopamine, Parkinson's disease and Monoamine oxidase inhibitor. In his articles, Mati Fridkin combines various disciplines, including Peptide and Magainin. His study focuses on the intersection of Chinese hamster ovary cell and fields such as Caspase 3 with connections in the field of Endocrinology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Enhancement of phagocytosis - a newly found activity of substance P residing in its N-terminal tetrapeptide sequence.
Z. Bar-Shavit;R. Goldman;Y. Stabinsky;P. Gottlieb.
Biochemical and Biophysical Research Communications (1980)
All-D-magainin : chirality, antimicrobial activity and proteolytic resistance
Roberto Bessalle;Aviva Kapitkovsky;Alfred Gorea;Itamar Shalit.
FEBS Letters (1990)
Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome
Miri Blank;Ilan Krause;Mati Fridkin;Nathan Keller.
Journal of Clinical Investigation (2002)
Antibodies against a synthetic peptide as a probe for the kinase activity of the avian EGF receptor and v-erbb protein
R.M. Kris;I. Lax;W. Gullick;M.D. Waterfield.
CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
Ofer Mandelboim;Gideon Berke;Mati Fridkin;Michael Feldman.
Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos
Pierre Gressens;Joanna M. Hill;Illana Gozes;Mati Fridkin.
Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes
Yoram Shechter;Itzhak Goldwaser;Marina Mironchik;Mati Fridkin.
Coordination Chemistry Reviews (2003)
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Hailin Zheng;Lev M. Weiner;Orit Bar-Am;Silvina Epsztejn.
Bioorganic & Medicinal Chemistry (2005)
Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides
Miri Blank;Yehuda Shoenfeld;Shmuel Cabilly;Yehudit Heldman.
Proceedings of the National Academy of Sciences of the United States of America (1999)
Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Hailin Zheng;Shunit Gal;Lev M. Weiner;Orit Bar-Am.
Journal of Neurochemistry (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: